Dasatinib + Quercetin ( DrugBank: Dasatinib, Quercetin )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 85 | 特発性間質性肺炎 | 1 |
85. 特発性間質性肺炎
臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02874989 (ClinicalTrials.gov) | December 16, 2016 | 17/8/2016 | Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial | Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Dasatinib + Quercetin;Drug: Placebo | Wake Forest University Health Sciences | Mayo Clinic;The University of Texas Health Science Center at San Antonio | Completed | 50 Years | N/A | All | 26 | Phase 1 | United States |